 MONTREAL, March 08, 2022 GLOBE NEWSWIRE -- Theratechnologies Inc. Theratechnologies or the Company TSX: TH NASDAQ: THTX, a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that three poster abstracts have been accepted for presentation at the 2022 Annual Meeting of the American Association for Cancer Research AACR to be held April 8-13, 2022 at the Ernest N. Morial Convention Center in New Orleans, Louisiana. The Company will present new in vivo TH1902 preclinical data demonstrating tumor growth inhibition of human cancer stem-like cells CD133 in both triple-negative breast and ovarian cancers. Theratechnologies will also present new in vivo data on anti-cancer efficacy of TH1902 against ovarian and endometrial cancers, in addition to the inhibitory effect of TH1902 on subcutaneous melanoma xenografts and formation of lung metastases in a syngeneic mouse model. 